The Company

Secretory IgA, Inc. is an early stage drug discovery and development company. The mission of this company is to develop orally available agents for the treatment of intestinal diseases mediated by bacterial toxins.

Secretory IgA, Inc.’s initial product is secretory immunoglobulin A (IgA). This biological therapeutic will treat Clostridium difficile-associated disease, a type of antibiotic-resistant intestinal disease caused by Clostridium difficile bacterial toxins. Clostridium difficile-associated disease can cause diarrhea, severe cramps and high fever. This condition may result in severe outcomes, such as surgical removal of the colon and death, especially in elderly patients and patients with compromised immune systems.

The secretory IgA will be administered by mouth and will pass to the colon, which is the site of the toxin production and tissue damage. In the colon, the secretory IgA will neutralize the bacterial toxins and thereby disrupt pathways leading to the patient’s disease.

Secretory IgA is expected to be safe and is similar in mode of action to other antibody treatments that are administered by injection or infusion. Secretory IgA, Inc. will design, develop and test these orally administered IgA antibodies.

Secretory IgA, Inc. is located in Ann Arbor, MI, USA.